Trametinib: A novel signal transduction inhibitor for the treatment of metastatic cutaneous melanoma [Clinical Review]

Trametinib: A novel signal transduction inhibitor for the treatment of metastatic cutaneous melanoma Skip to main page content

HOME CURRENT ISSUE PAST ISSUES SUPPLEMENTS REPRINTS ALERTS KEYWORDS GO Advanced Search ? Advertisement
Trametinib: A novel signal transduction inhibitor for the treatment of metastatic cutaneous melanoma Clement Chung? and Sean Reilly

Clement Chung, Pharm.D., BCOP, BCPS, is Oncology Clinical Pharmacist, Lyndon B. Johnson General Hospital; and Sean Reilly, B.S.Pharm., Pharm.D., is Oncology Clinical Pharmacist, Ben Taub General Hospital, Harris Health System, Houston, TX. Address correspondence to Dr. Chung (clement_t_chung{at}yahoo.com). Abstract Purpose The pharmacology, pharmacokinetics, clinical efficacy, safety, administration, cost, and place in therapy of trametinib for the treatment of metastatic melanoma are reviewed.

Summary Approximately 40–60% of malignant melanomas have gene mutations at codon 600 of the BRAF gene that result in the activation of the mitogen-activated protein kinase (MAPK) pathway. Trametinib is the first-in-class mitogen-activated, extracellular signal-regulated kinase (MEK) inhibitor that targets a kinase in the MAPK pathway that plays a key role in oncogenic cell proliferation, survival, invasion, tumor angiogenesis, and escape from apoptosis. It is approved by the Food and Drug Administration for use in patients whose tumors express the BRAF V600E or V600K gene mutations. Moreover, trametinib is also indicated for use in combination with dabrafenib (a BRAF inhibitor). Trametinib is not indicated in patients who have received prior BRAF-inhibitor therapy due to poor response and possible cross-resistance. The most common adverse effects associated with the use of trametinib for both monotherapy and combination therapy are rash, diarrhea, peripheral edema, fatigue, and dermatitis. The recommended dosage of trametinib monotherapy is 2 mg orally once daily until disease progression or unacceptable toxicity occurs. With a daily dose of 2 mg, an estimated 30-day course of treatment would cost approximately $9135.

Conclusion Trametinib, a novel MEK inhibitor, provides an alternative therapy for patients with BRAF V600 E/K metastatic melanoma as a single agent or in combination therapy for patients not previously treated with a BRAF inhibitor. More studies are needed to determine the safe and effective combination or sequencing of trametinib with other therapies.

Copyright ? 2015 by the American Society of Health-System Pharmacists, Inc. All rights reserved. CiteULike Delicious Digg Facebook Google+ Reddit Twitter What's this?

? Previous | Next Article ? Table of Contents This Article doi: 10.2146/ajhp140045 American Journal of Health-System Pharmacy January 15, 2015 vol. 72 no. 2 101-110 ? Abstract Full Text Full Text (PDF) Classifications Print Content Clinical Review Services Email this article to a colleague Alert me when this article is cited Alert me if a correction is posted Alert me when eLetters are published Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Download to citation manager eLetters Submit an eLetter No eLetters published Citing Articles Load citing article information Google Scholar Articles by Chung, C. Articles by Reilly, S. PubMed PubMed citation Articles by Chung, C. Articles by Reilly, S. Related Content Load related web page information Social Bookmarking CiteULike Delicious Digg Facebook Google+ Reddit Twitter What's this?

Current Issue February 15, 2015, 72 (4) Alert me to new issues of American Journal of Health-System Pharmacy From the Cover RhOD immune globulin products for prevention of alloimmunization during pregnancy Sublingual tacrolimus as an alternative to oral administration for solid organ transplant recipients Economic burden of recurrent venous thromboembolism: Analysis from a U.S. hospital perspective Comparative analytics of infusion pump data across multiple hospital systems ABOUT AJHP SUBSCRIPTIONS FOR AUTHORS/REVIEWERS PERMISSION REQUESTS ADVERTISING EMAIL ALERTS (FREE) RSS FEEDS (FREE) HELP CONTACT US/FEEDBACK American Society of Health System Pharmacists Learning Center (CE) Store Meetings & Conferences ASHP Foundation MOST READ ARTICLES (Last 30 Days) Clinical practice guidelines for antimicrobial prophylaxis in surgery Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists How to write a patient case report Treatment of poisoning caused by {beta}-adrenergic and calcium-channel blockers ? View all Most Read articles Advertisement ? 2015 by the American Society of Health-System Pharmacists. Terms of Use | Copyright Online ISSN: 1535-2900 Print ISSN: 1079-2082

View the original article here